REVIEW: AVAILABLE ANALYTICAL METHODS FOR THE ESTIMATION OF FIRST LINE, SECOND LINE ORAL AND NEWER ANTI-TB DRUGSAbstract
Tuberculosis (TB) is one of the top ten causes of death worldwide. Presently, one-quarter of the world’s population is thought to be infected with TB. New infections occur in about 1% of the population each year. Tuberculosis is a major global health threat. There is a progressive increase in multidrug-resistant (MDR) and extensively drug-resistant tuberculosis (XDR). Multi drug resistance (MDR)-TB and Extensively drug resistance (XDR)-TB poses a vital challenge to the control of tuberculosis. Numbers of drugs are available in the market for the treatments of tuberculosis as well as many new drugs are also available for the treatment of MDR-TB and XDR-TB. This review article covers most of the different official and reported analytical methods for the estimation of the first line, second line oral, and newer anti-TB drugs. The main objective of this review is to classify, summarize, and discusses the different proposed analytical methods for the estimation of above mentioned anti-TB drugs alone and in combination with other drugs in bulk, pharmaceutical formulation and biological matrices.
R. J. Jani * and P. U. Patel
Department of Quality Assurance, Shree S. K. Patel College of Pharmaceutical Education & Research, Ganpat University, Mehsana, Gujarat, India.
25 April 2020
10 November 2020
12 April 2021
01 May 2021